➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Last Updated: April 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for DEBIO-1347

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for DEBIO-1347?

DEBIO-1347 is an investigational drug.

There have been 21 clinical trials for DEBIO-1347. The most recent clinical trial was a Phase 2 trial, which was initiated on July 15th 2020.

The most common disease conditions in clinical trials are Bacterial Infections, Infection, and Hepatitis C. The leading clinical trial sponsors are Debiopharm International SA, Parexel, and GORTEC (Head and Neck Oncology and Radiotherapy Group).

There are five US patents protecting this investigational drug and eighty-two international patents.

Recent Clinical Trials for DEBIO-1347
TitleSponsorPhase
A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive ChemoradiotGORTEC (Head and Neck Oncology and Radiotherapy Group)Phase 3
A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive ChemoradiotDebiopharm International SAPhase 3
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsDebiopharm International SAPhase 1

See all DEBIO-1347 clinical trials

Clinical Trial Summary for DEBIO-1347

Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347

See all DEBIO-1347 clinical trials

US Patents for DEBIO-1347

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DEBIO-1347   Start Trial FGFR gatekeeper mutant gene and drug targeting same Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)   Start Trial
DEBIO-1347   Start Trial FGFR3 fusion gene and pharmaceutical drug targeting same Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)   Start Trial
DEBIO-1347   Start Trial Aminopyrazole derivative Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH)   Start Trial
DEBIO-1347   Start Trial Aminopyrazole derivative Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH)   Start Trial
DEBIO-1347   Start Trial Pharmaceutical preparation comprising aminopyrazole derivative Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DEBIO-1347

Drugname Country Document Number Estimated Expiration Related US Patent
DEBIO-1347 Denmark DK3087986 2033-12-27   Start Trial
DEBIO-1347 European Patent Office EP3087986 2033-12-27   Start Trial
DEBIO-1347 European Patent Office EP3581179 2033-12-27   Start Trial
DEBIO-1347 Spain ES2756175 2033-12-27   Start Trial
DEBIO-1347 Japan JP6514645 2033-12-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.